Evidence map›Paper›PMID 28212067›Full record

Trial reportJournal of child and adolescent psychopharmacology2017

The Treatment of Severe Childhood Aggression Study: 12 Weeks of Extended, Blinded Treatment in Clinical Responders.

Robert L Findling, Lisa Townsend, Nicole V Brown, L Eugene Arnold, Kenneth D Gadow, David J Kolko, Nora K McNamara, Devin S Gary, Dana B Kaplin, Cristan A Farmer and 8 more

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Robert L Findling1 Division of Child and Adolescent Psychiatry, Johns Hopkins University , Baltimore, Maryland.
Lisa Townsend1 Division of Child and Adolescent Psychiatry, Johns Hopkins University , Baltimore, Maryland.
Nicole V Brown4 Center for Biostatistics, Ohio State University Medical Center , Columbus, Ohio.
L Eugene Arnold5 Department of Psychiatry, Ohio State University , Columbus, Ohio.
Kenneth D Gadow6 Department of Psychiatry, Stony Brook University , Stony Brook, New York.
David J Kolko7 Department of Psychiatry and Psychology, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.
Nora K McNamara8 Department of Psychiatry, Case Western Reserve University , Cleveland, Ohio.
Devin S Gary2 Department of Psychiatry, Kennedy Krieger Institute , Baltimore, Maryland.
Dana B Kaplin1 Division of Child and Adolescent Psychiatry, Johns Hopkins University , Baltimore, Maryland.
Cristan A Farmer9 Pediatrics & Developmental Neuroscience Branch, National Institute of Mental Health , Bethesda, Maryland.
Heidi Kipp7 Department of Psychiatry and Psychology, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.
Craig Williams10 The Nisonger Center (UCEDD), Ohio State University , Columbus, Ohio.
Eric M Butter11 Division of Pediatric Psychology and Neuropsychology, Nationwide Children's Hospital , Columbus, Ohio.
Oscar G Bukstein12 Harvard University Children's Hospital , Boston, Massachusetts.
Robert Rice10 The Nisonger Center (UCEDD), Ohio State University , Columbus, Ohio.
Kristin Buchan-Page10 The Nisonger Center (UCEDD), Ohio State University , Columbus, Ohio.
Brooke S G Molina7 Department of Psychiatry and Psychology, University of Pittsburgh School of Medicine , Pittsburgh, Pennsylvania.
Michael G Aman10 The Nisonger Center (UCEDD), Ohio State University , Columbus, Ohio.

Funding

UNIVERSITY OF PITTSBURGH CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE: BPCAUL1RR024153 · NCRR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2006 to 2011
$73.9M
University of Pittsburgh Clinical and Translational Science InstituteUL1TR000005 · NCATS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI REIS, STEVEN E · 2012 to 2015
$50.8M
World Trade Center Worker and Volunteer Medical Screening ProgramM01RR010710 · NCRR · STATE UNIVERSITY NEW YORK STONY BROOK · PI GOLDSTEIN, RITA Z · 1998 to 2009
$17.6M
1/4-Stimulant and Risperidone for Youth with Severe Physical AggressionR01MH077907 · NIMH · OHIO STATE UNIVERSITY · PI AMAN, MICHAEL GEORGE · 2008 to 2011
$1.9M
3/4-Stimulant and Risperidone for Youth with Severe Physical AggressionR01MH077750 · NIMH · CASE WESTERN RESERVE UNIVERSITY · PI MCNAMARA, NORA · 2008 to 2011
$1.6M
2/4-Stimulant and Risperidone for Youth with Severe Physical AggressionR01MH077676 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI MOLINA, BROOKE S.G. · 2008 to 2011
$1.6M
4/4-Stimulant and Risperidone for Youth with Severe Physical AggressionR01MH077997 · NIMH · STATE UNIVERSITY NEW YORK STONY BROOK · PI GADOW, KENNETH D · 2008 to 2011
$1.5M
NCATS NIH HHS UL1 TR000005NCRR NIH HHS M01 RR010710NCRR NIH HHS UL1 RR024153NIMH NIH HHS R01 MH077676NIMH NIH HHS R01 MH077750NIMH NIH HHS R01 MH077907NIMH NIH HHS R01 MH077997
6 · The paper itself

Abstract

objectivesPrevious "Treatment of Severe Childhood Aggression" (TOSCA) reports demonstrated that many children with severe physical aggression and attention-deficit/hyperactivity disorder (ADHD) responded well to two randomized treatments (parent training [PT]+stimulant+placebo = Basic vs. PT+stimulant+risperidone = Augmented) for 9 weeks. An important clinical question is whether these favorable outcomes are maintained over longer times.

methodsClinical responders to the 9-week trial (n = 103/168), defined as Clinical Global Impressions (CGI)-Improvement of much/very much improved plus substantial reduction in parent ratings of disruptiveness, were followed another 12 weeks (21 weeks total) while remaining on blinded treatment. Outcome measures included Clinical Global Impressions scale, Nisonger Child Behavior Rating Form (NCBRF), other parent/teacher-rated scales, laboratory tests, clinician ratings of abnormal movement, and other adverse events (AEs).

resultsParent ratings of problem behavior showed minimal worsening of behavior from end of the 9-week acute trial (expected from regression to the mean after selecting best responders), but outcomes at Extension endpoint were meaningfully improved compared with acute study baseline. As expected, outcomes for Basic and Augmented treatment did not differ among these children selected for good clinical response. During Extension, more Augmented subjects had elevated prolactin; there were no clinically confirmed cases of tardive dyskinesia. Delayed sleep onset was the most frequent Basic AE. We also conducted a last-observation-carried-forward analysis, which included both nonresponders and responders. We found that, at the end of Extension, Augmented subjects had more improvement than Basic subjects on the NCBRF Positive Social subscale (p = 0.005; d = 0.44), the Antisocial Behavior Scale Reactive Aggression subscale (p = 0.03; d = 0.36), and marginally so on the Disruptive Behavior Total subscale (p = 0.058; d = 0.29, the primary outcome).

conclusionsThe medium-term outcomes were good for the participants in both treatment groups, perhaps because they were selected for good response. When nonresponders were included in ITT analyses, there was some indication that Augmented surpassed Basic treatment.

Indexed as

AggressionAntipsychotic AgentsAttention Deficit Disorder with HyperactivityCentral Nervous System StimulantsChildCombined Modality TherapyDouble-Blind MethodFemaleHumansMaleParentsPsychiatric Status Rating ScalesRisperidoneSeverity of Illness IndexTime FactorsTreatment OutcomeAntipsychotic AgentsCentral Nervous System StimulantsRisperidoneaggressionclinical trialdisruptive behavior disordersstimulant

Identifiers

PMID28212067
PMCPMC5327034

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.